Alpha Teknova (TKNO)
NASDAQ:TKNO
Want to see TKNO full AI Analyst Report?
Top Page
Alpha Teknova
(NASDAQ:TKNO)
Select Model
Select Model
Rating:53Neutral
Price Target:
$3.50
▲(55.56% Upside)
Action:ReiteratedDate:05/01/26
The score is primarily held back by weak financial performance (ongoing losses and negative free cash flow despite improvement). Technicals are supportive with improving momentum, while valuation is constrained by lack of profitability. The earnings call adds moderate support due to improving operating trends and clearer targets, but guidance still implies continued cash burn and only modest near-term growth.
Positive Factors
Sustained revenue growth
Six consecutive quarters of revenue growth and FY2025 top-line expansion demonstrate that demand and execution are re-accelerating. Durable revenue momentum supports scaling manufacturing, validates product-market fit for catalog and custom offerings, and underpins a credible path to steady annual revenue growth if sustained.
Negative Factors
Ongoing negative free cash flow
Persistent negative operating and free cash flow means the business still depends on balance-sheet resources or external financing to fund growth and operations. Even with improvement, recurring cash burn constrains flexibility for investment, increases refinancing risk, and could pressure strategic options if not reversed to sustainable positive FCF.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained revenue growth
Six consecutive quarters of revenue growth and FY2025 top-line expansion demonstrate that demand and execution are re-accelerating. Durable revenue momentum supports scaling manufacturing, validates product-market fit for catalog and custom offerings, and underpins a credible path to steady annual revenue growth if sustained.
Read all positive factors
Alpha Teknova (TKNO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$182.27M
Dividend YieldN/A
Average Volume (3M)318.88K
Price to Earnings (P/E)―
Beta (1Y)1.03
Revenue Growth7.35%
EPS Growth44.64%
CountryUS
Employees173
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.33
Shares Outstanding53,610,200
10 Day Avg. Volume259,294
30 Day Avg. Volume318,881
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)2.96
Price to Sales (P/S)5.02
P/FCF Ratio-22.01
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue4.73
Enterprise Value/Gross Profit14.25
Enterprise Value/Ebitda-18.01
Forecast
1Y Price Target
$7.00Price Target Upside211.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$43.02M
Alpha Teknova Business Overview & Revenue Model
Company Description
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines,...
How the Company Makes Money
Alpha Teknova makes money by selling life-sciences reagents and related materials to customers that need consistent, scalable inputs for laboratory and pre-commercial/clinical workflows. Its revenue model is largely product sales and manufacturing...
Alpha Teknova Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 06, 2026
Earnings Call Sentiment Positive
The call portrayed clear operational and financial progress: revenue growth (6th straight quarter), improved gross margins, narrower net losses and adjusted EBITDA, better free cash flow performance, growing clinical customer count and pipeline progress. Management is beginning to reinvest (~$2M) in commercial capabilities, providing a plausible path to adjusted EBITDA positivity by end of 2027 (targeting $52M–$57M annualized revenue). Key near-term risks include ongoing negative adjusted EBITDA and free cash outflow, lowered average revenue per customer from new/early-stage accounts, revenue lumpiness in Clinical Solutions, and reliance on a sustained biotech funding recovery (with a ~4-quarter lag) to accelerate revenue. Overall, the company is trending in the right direction but still requires execution and favorable market conditions to meet longer-term targets.Positive Updates
Revenue Growth and Momentum
Total revenue of $40.5M in FY2025, a 7% increase from $37.7M in FY2024; Q4 revenue $10.0M, up 8% YoY. This marks the company's sixth consecutive quarter of revenue growth.
Negative Updates
Continued Negative Adjusted EBITDA and Cash Burn
Adjusted EBITDA remained negative $6.7M for FY2025 and free cash flow was negative $9.8M, indicating ongoing cash burn despite improvements; management forecasts continued negative free cash outflow (< $10M) in 2026 due to new commercial spend.
Read all updates
Q4-2025 Updates
Positive
Negative
Revenue Growth and Momentum
Total revenue of $40.5M in FY2025, a 7% increase from $37.7M in FY2024; Q4 revenue $10.0M, up 8% YoY. This marks the company's sixth consecutive quarter of revenue growth.
Read all positive updates
Company Guidance
Teknova guided 2026 revenue of $42.0–$44.0 million (midpoint ≈6% growth vs $40.5M in 2025), expects gross margin in the mid‑30s (vs 33.2% in 2025), and will increase sales & marketing spend by about $2.0 million while targeting free cash flow outflow of less than $10.0 million (2025 FCF outflow was $9.8M, below prior <$12M guidance). Management reiterated that each incremental dollar of revenue drops to the bottom line at roughly a 70% marginal cash rate (with some quarter‑to‑quarter GAAP variability) and said it is targeting adjusted EBITDA positivity by the end of 2027 once annualized revenue reaches roughly $52–$57M (about $13–$14M per quarter); longer‑term aspirations include 60–65% gross margins and 25–30% adjusted EBITDA margins. They also noted a ~4‑quarter lag between biotech funding and revenue, so sustained increases in funding could drive biopharma revenue growth beginning in Q4 2026 and create upside to 2026 guidance.Alpha Teknova Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
58
Neutral
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 40.52M | 37.74M | 36.68M | 41.42M | 36.89M |
| Gross Profit | 13.44M | 7.23M | 10.30M | 17.48M | 17.62M |
| EBITDA | -10.15M | -19.57M | -25.54M | -25.69M | -9.13M |
| Net Income | -17.26M | -26.75M | -36.78M | -47.47M | -9.80M |
Balance Sheet | |||||
| Total Assets | 103.58M | 118.77M | 128.59M | 152.26M | 166.51M |
| Cash, Cash Equivalents and Short-Term Investments | 5.91M | 30.40M | 28.48M | 42.24M | 87.52M |
| Total Debt | 15.15M | 30.17M | 30.46M | 42.31M | 11.87M |
| Total Liabilities | 34.81M | 36.38M | 38.55M | 52.38M | 23.31M |
| Stockholders Equity | 68.78M | 82.39M | 90.04M | 99.89M | 143.20M |
Cash Flow | |||||
| Free Cash Flow | -9.23M | -13.52M | -26.75M | -55.55M | -28.95M |
| Operating Cash Flow | -8.08M | -12.39M | -18.81M | -27.40M | -9.07M |
| Investing Cash Flow | 10.70M | -27.27M | -7.74M | -28.15M | -17.52M |
| Financing Cash Flow | 151.00K | 14.89M | 12.80M | 10.27M | 110.79M |
Alpha Teknova Technical Analysis
Positive
2.25
Price Trends
2.56
Positive
3.28
Negative
4.07
Negative
Market Momentum
0.04
Positive
53.46
Neutral
29.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TKNO, the sentiment is Positive. The current price of 2.25 is below the 20-day moving average (MA) of 2.89, below the 50-day MA of 2.56, and below the 200-day MA of 4.07, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 53.46 is Neutral, neither overbought nor oversold. The STOCH value of 29.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TKNO.
Alpha Teknova Risk Analysis
Alpha Teknova disclosed 70 risk factors in its most recent earnings report. Alpha Teknova reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Alpha Teknova Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $723.98M | 22.76 | -8.22% | ― | -15.72% | 1233.64% | |
53 Neutral | $182.27M | -10.69 | -23.32% | ― | 7.35% | 44.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $745.44M | -4.58 | -27.86% | ― | ― | -9.36% | |
48 Neutral | $197.13M | -9.61 | -182.11% | ― | 0.47% | -430.88% | |
48 Neutral | $141.85M | -16.52 | -46.40% | ― | 10.20% | 35.27% |
* Healthcare Sector Average
TKNO
Alpha Teknova
3.40
-2.61
-43.43%
IRWD
Ironwood Pharma
4.44
3.51
378.96%
LFCR
Lifecore Biomedical
5.26
-1.76
-25.07%
SXTC
China SXT Pharmaceuticals
2.07
-209.43
-99.02%
DERM
Journey Medical Corp
5.19
-1.68
-24.45%
BIOA
BioAge Labs, Inc.
16.79
12.64
304.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.